Wednesday, 5 November 2014

Ghana: WHO welcomes Swiss medic Ebola vaccine trial

The World Health Organization (WHO) has welcomed the approval by Swissmedic, the Swiss regulatory authority for therapeutic products, for a trial with an experimental Ebola vaccine at the Lausanne University Hospital (CHUV).

“This marks the latest step towards bringing safe and effective Ebola vaccines for testing and implementation as quickly as possible,” a WHO press release made available to the Ghanaian media stated.

The approval means that the vaccine can be used on approximately 120 individuals in Lausanne. The trial, which is receiving support from WHO, is the latest in a series of trials that are ongoing in Mali, the United Kingdom, and the United States, the statement said.

The WHO statement explained that the vaccine is based on a genetically modified chimpanzee adenovirus ("ChAd-Ebola"; Chimpanzee-Adenovirus chAD3-ZEBOV).

The trial will test the safety of the vaccine and its capacity to induce an immune response, results from the CHUV trial will – together with the results of other centres involved – provide the basis for planning subsequent trials involving several thousand participants, and for choosing vaccine dose-level for efficacy trials. Read More...


Post a Comment